{
    "pmcid": "11100608",
    "qa_pairs": {
        "What future direction does the study suggest for optimizing bispecific constructs?": [
            "Exploring additional antibody pairings and improving expression and purification processes.",
            "Developing oral formulations of bispecific antibodies.",
            "Focusing solely on targeting the antigenic supersite.",
            "Increasing the size of nanobodies for better stability."
        ],
        "What is the primary advantage of nanobodies over conventional antibodies in targeting SARS-CoV-2 spike protein?": [
            "Their small size allows them to access cryptic epitopes.",
            "They have a higher binding affinity to the spike protein.",
            "They are more cost-effective to produce.",
            "They can be administered orally."
        ],
        "What is the primary goal of designing bispecific antibodies like CoV2-biRN5 and CoV2-biRN7?": [
            "To enhance neutralization potency and breadth against all tested Omicron variants.",
            "To reduce production costs of antibody therapeutics.",
            "To target only the RBD domain of the spike protein.",
            "To increase the half-life of antibodies in the bloodstream."
        ],
        "What structural feature of C1596 contributes to its broad neutralization capability?": [
            "Binding to a glycopeptidic epitope on the NTD with additional interactions involving the RBD and SD1 domains.",
            "Exclusive binding to the RBD domain.",
            "Binding to a highly mutable antigenic supersite.",
            "Inducing a 'down' state in the RBD."
        ],
        "Which specific nanobody is noted for its broad cross-reactivity and potent neutralization across various VOCs, including Omicron subvariants?": [
            "C1596",
            "C952",
            "CoV2-biRN5",
            "CoV2-biRN7"
        ]
    }
}